Last reviewed · How we verify
Pfizer/Wyeth
This drug targets the PD-1 receptor to inhibit cancer cell growth.
This drug targets the PD-1 receptor to inhibit cancer cell growth. Used for Non-small cell lung cancer, PD-L1 positive, Melanoma.
At a glance
| Generic name | Pfizer/Wyeth |
|---|---|
| Sponsor | D'Or Institute for Research and Education |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to the PD-1 receptor, the drug prevents cancer cells from evading the immune system, allowing the body's immune cells to attack and destroy the cancer cells. This results in a more effective anti-tumor response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Melanoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Diarrhea
Key clinical trials
- Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes. (PHASE3)
- An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens (PHASE3)
- Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) (PHASE4)
- Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules in Chinese Healthy Volunteers (NA)
- Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants (PHASE1, PHASE2)
- Physicians' Health Study II (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pfizer/Wyeth CI brief — competitive landscape report
- Pfizer/Wyeth updates RSS · CI watch RSS
- D'Or Institute for Research and Education portfolio CI